2 research outputs found
Gene expression analysis of hormone receptor positive breast cancer under the age of 35
νμλ
Όλ¬Έ (λ°μ¬)-- μμΈλνκ΅ λνμ : μκ³Όλν μνκ³Ό μΈκ³Όνμ 곡, 2016. 2. λ
Έλμ.35 μΈ λ―Έλ§μμμ μ λ°©μμ μμ보λ€λ λμμμ μλμ μΌλ‘ λΉλκ° λλ€. κ·Έλ¦¬κ³ μ΄ κ²½μ° μΌλ°μ μΌλ‘ μνκ° λμλ©°, νΉν μ¬μ±νΈλ₯΄λͺ¬ μμ©μ²΄ μμ±μ μ λ°©μμμλ ννΈλ₯΄λͺ¬μΉλ£λ₯Ό λ°μ κ²½μ°λΌλ λ€λ₯Έ μ°λ Ήμ κ°μ κ²½μ°μ λΉν΄ μνκ° μ’μ§ μλ€. κ·ΈλΌμλ μ΄λ¬ν μμ κ²°κ³Όμ λν κΈ°μ μ μ μλ €μ Έ μμ§ μλ€. λ°λΌμ λ³Έ μ°κ΅¬μμλ μ΄μ κ°μ΄ λμ μνμ μμμ κ²°κ³Όλ₯Ό λ³΄μ¬ μ£Όλ 35 μΈ λ―Έλ§ μ¬μ±νΈλ₯΄λͺ¬ μμ©μ²΄ μμ± μ λ°©μμμμ νΉμ§μ μΈ μ μ μ λ°ν μμμ λ³΄κ³ μ νλ€.
λ³Έ μ°κ΅¬μμλ 35 μΈ λ―Έλ§μ μ¬μ±νΈλ₯΄λͺ¬ μμ©μ²΄ μμ± μ λ°©μ μ‘°μ§κ³Ό 40 μΈ μ΄μ νκ²½ μ μ¬μ±μμμ μ¬μ±νΈλ₯΄λͺ¬ μμ©μ²΄ μμ± μ λ°©μ μ‘°μ§μ μ΄μ©νμ¬ cDNA microarray λ₯Ό μννμκ³ , μ΄λ₯Ό ν΅ν΄ λ κ΅°κ° μ μν λ°νμ μ°¨μ΄λ₯Ό 보μ΄λ μ μ μλ€μ νμΈνκ³ , μ΄λ€ μ μ μλ€μ μ΄μ©νμ¬ pathway analysis λ₯Ό νμλ€. κ·Έλ¦¬κ³ 120 λͺ
μ μ λ°©μ μ‘°μ§μ μ΄μ©ν whole transcriptome sequencing μ μννμ¬ μ΄λ‘λΆν° μ»μ΄μ§ λ°μ΄ν°μμ μμ€νΈλ‘μ μμ©μ²΄ μμ± μ λ°©μ λ° μΈν¬ μ£ΌκΈ°μ κ΄λ ¨λ μ μ μλ€μ μ μ νμλ€. κ·Έ λ€μ, μΉ κΈ°λ°μ νλ‘κ·Έλ¨ (Kaplan-Meier plotter,
SurvExpress)μ ν΅ν΄ μ΄ μ μ μλ€μ μμμ κ²°κ³Όλ€μ λν μμΈ‘λ ₯μ μ€ν μμ€ μ μ μ λ°ν λ°μ΄ν°λ€μ μ΄μ©νμ¬ κ²μ¦νμλ€. μ΅μ’
μ μΌλ‘ 35 μΈ λ―Έλ§μ μ¬μ±νΈλ₯΄λͺ¬ μμ©μ²΄ μμ± μ λ°©μ μ‘°μ§κ³Ό κ·Έμ λμνλ 40 μΈ μ΄μ 49 μΈ μ΄νμ μ¬μ±νΈλ₯΄λͺ¬ μμ©μ²΄ μμ± μ λ°©μ μ‘°μ§μ μ΄μ©νμ¬, μ μ λ μ μ μκ΅°μ λ°νμ RNA sequencing μ ν΅ν΄ λΉκ΅ νμΈνμλ€.
cDNA microarray κ²°κ³Όμ μΈν¬ μ¦μκ³Ό κ΄λ ¨λ μ μ μλ€μ λ°νμ΄ 35 μΈ λ―Έλ§μ μ¬μ±νΈλ₯΄λͺ¬ μμ©μ²΄ μμ± μ λ°©μ μ‘°μ§μμ λκ² λμκ³ , μ΄λ€ μ μ μλ€μ μ΄μ©ν pathway analysis κ²°κ³Ό, μΈν¬ μ£ΌκΈ°μ κ΄λ ¨λ pathway κ° μ μνκ² λνλ¬λ€. μ΄ κ²°κ³Όμ Whole transcriptome sequencing κ²°κ³Όλ₯Ό μ΄μ©νμ¬ μμ€νΈλ‘κ² μμ©μ²΄ μμ± μ λ°©μμμ λ°νμ΄ λμ μμ 40 κ°μ μ μ μλ€κ³Ό μΈν¬ μ£ΌκΈ°μ κ΄λ ¨νμ¬ μ£Όμν μ μ μμΈ CCNB1 κ³Ό λ°ν μ
λμ μκ΄μ±μ 보μ¬μ€ μμ 40 κ°μ μ μ μλ€μ μ μ νμ¬ μ΄ 80 κ°μ μ μ μκ΅°μ λ§λ€μλ€. Kaplan-Meier plotter μ SurvExpress λ‘ μ€ν μμ€ λ°μ΄ν°λ₯Ό ν΅ν΄ μν μ°κ΄μ±μ λν΄ κ²μ¦νμλλ° Kaplan-Meier plotter μμλ μ μ μκ΅°μ νκ· λ°νμΌλ‘ λλ λ κ΅°μμ μΈν¬ μ£ΌκΈ° κ΄λ ¨ μ μ μλ€μ λ°νμ΄ λμ κ²½μ° recurrence-free survival μ λν Hazard ratio κ° 2.66(log rank p=8.4e-11)λ‘ λμμΌλ©°, SurvExpress λ‘ μνν
κ²μ¦μμλ μ μ μκ΅°μ λ°νμ λ°λ₯Έ μνλλ₯Ό λλ λ κ΅°μ 4 κ°μ μ€ν μμ€ λ°μ΄ν°μμ λ³Έ κ²°κ³Ό, μ λ°©μ νμλ€μ μνλ₯Ό μ μνκ² λλ μ μμλ€. κ·Έλ¦¬κ³ targeted RNA sequencing κ²°κ³Ό 35 μΈ λ―Έλ§μ μ¬μ±νΈλ₯΄λͺ¬ μμ©μ²΄ μμ± μ λ°©μ μ‘°μ§μμ κ°μ 쑰건μ 40 λμ λΉν΄ λμ λ°νμ 보μ΄λ μΈν¬ μ£ΌκΈ° κ΄λ ¨ μ μ μλ€μ΄ λ§μλ€.
μ 리νλ©΄ 35 μΈ λ―Έλ§μ μ¬μ±νΈλ₯΄λͺ¬ μμ©μ²΄ μμ±μ μ λ°©μμ κ·Έ μ΄μ μ°λ Ήμ νκ²½ μ μ¬μ±νΈλ₯΄λͺ¬ μμ©μ²΄ μμ± μ λ°©μμ λΉν΄ μΈν¬ μ£ΌκΈ°μ κ΄λ ¨λ μ μ μ λ°νμ΄ λκ³ , μ΄λ¬ν νΉμ§μ΄ μμμ μΌλ‘ λμ μνλ₯Ό λνλ΄λ μμΈμ΄ λ μ μλ€.μλ‘ 1
μ λ°©μμ νν© 1
35μΈ λ―Έλ§μ μ¬μ±μμ λ°μν μ λ°©μμ λμ μν 2
35μΈ λ―Έλ§ μ¬μ±μμμ μ λ°©μμμ λμ μνμ κ΄λ ¨λ μμλ³λ¦¬ μΈμλ€ 4
35μΈ λ―Έλ§ μ¬μ±μμμ μ¬μ±νΈλ₯΄λͺ¬ μμ©μ²΄ μμ± μ λ°©μμ λμ μν 7
μ μ μ¬μ± μ λ°©μμ λΆμ μλ¬Όνμ νΉμ§ 11
λ³Έ μ°κ΅¬μ λͺ©μ 13
μ°κ΅¬λ°©λ² 16
cDNA microarray 16
Whole transcriptome sequencing 17
In silico validation 18
Targeted RNA sequencing 19
μ°κ΅¬κ²°κ³Ό 22
Analysis of cDNA microarray 22
Selection of genes by whole transcriptome sequencing data 28
In silico validation 35
Targeted RNA sequencing 41
κ³ μ°° 47
μ°Έκ³ λ¬Έν 57
Abstract 65Docto
The Impact of Primary Tumor Resection on the Survival of Patients with Stage IV Breast Cancer
Purpose The main treatment for stage IV breast cancer is currently systemic therapy. Surgical resection of the primary tumor is usually done for treating the tumor-related complications Recent studies have suggested that surgery may improve the long-term survival of stage IV breast cancer patients We evaluated the impact of the primary surgical resection site on the survival of stage IV breast cancer patients. Methods We reviewed the records of the stage IV breast cancer patients who were treated at Seoul University Hospital between April 1992 and December 2007 The tumor and clinical characteristics, the type of treatments and the overall survival were compared between the surgically versus nonsurgically treated patients. Results. Of the 198 identified patients, 110 (55 8%) received surgical excision of their primary tumor and 88 (44 2%) did not The mean survival was 67 months vs. 42 months for the surgically treated patients vs the patients without surgery, respectively (p=0 0287) On a multivariate analysis with using the Cox model and after adjusting for the estrogen receptor status, visceral metastases, the number of metastatic sites and trastuzumab treatment, surgery was an independent factor for improved survival (hazard ratio, 0.55; 95% confidence interval, 0.31-0.97; p=0.041). Conclusion Surgical resection of the primary tumor in stage IV breast cancer patients was independently associated with improved survival. Randomized prospective trials are needed to firmly recommend surgical resection of the primary tumor in stage IV breast cancer patientsλ³Έ μ°κ΅¬λ νμ, μ λ°©μ/λμμ μ μ 체 μ°κ΅¬μΌν°μ μ°κ΅¬λΉλ₯Ό μ§μλ°μ μν
λμμ(01-PJ3-PG6-01GN07-0004).Bafford AC, 2009, BREAST CANCER RES TR, V115, P7, DOI 10.1007/s10549-008-0101-7Blanchard DK, 2008, ANN SURG, V247, P732, DOI 10.1097/SLA.0b013e3181656d32*KOR BREAST CANC S, 2008, BREAST CANC FACTS FI, V1, P5Fields RC, 2007, ANN SURG ONCOL, V14, P3345, DOI 10.1245/s10434-007-9527-0Gnerlich J, 2007, ANN SURG ONCOL, V14, P2187, DOI 10.1245/s10434-007-9438-0Rapiti E, 2006, J CLIN ONCOL, V24, P2743, DOI 10.1200/JCO.2005.04.2226Morrow M, 2006, J CLIN ONCOL, V24, P2694, DOI 10.1200/JCO.2006.05.9824Babiera GV, 2006, ANN SURG ONCOL, V13, P776, DOI 10.1245/ASO.2006.03.033Hotta T, 2006, ANTICANCER RES, V26, P1377Abe O, 2005, LANCET, V366, P2087Andre F, 2004, J CLIN ONCOL, V22, P3302, DOI 10.1200/JCO.2004.08.095Giordano SH, 2004, CANCER, V100, P44, DOI 10.1002/cncr.11859Khan SA, 2002, SURGERY, V132, P620, DOI 10.1067/msy.2002.127544Flanigan RC, 2001, NEW ENGL J MED, V345, P1655Demicheli R, 2001, BRIT J CANCER, V85, P490Dauplat J, 2000, SEMIN SURG ONCOL, V19, P42Overgaard M, 1999, SEMIN RADIAT ONCOL, V9, P292DOGHETTO GB, 1999, AM SURGEON, V65, P352BLAND KI, 1998, BREAST COMPREHENSIVE, V2Ragaz J, 1997, NEW ENGL J MED, V337, P956OREILLY MS, 1994, CELL, V79, P315FISHER B, 1989, CANCER RES, V49, P1996*NAT CANC I, BREAST CANC TREATM P